trial · primary record
Xaluritamig
Ewing Sarcoma
| Phase | Phase 1 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 50 |
| Primary completion | 2030-05-26 |
| Primary endpoint | Number of Participants Experiencing a Dose-limiting Toxicity (DLT) (Part 1 Only) |
| Registry ID | NCT07297979 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-29T14:32:12.631Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07297979
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.